Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 331-334

  Deron, Philippe B ^a   Bonte, Katrien M ^a   Vermeersch, Hubert F ^a   Van De Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

computed tomography; head and neck; positron emission tomography; squamous cell carcinoma; unknown primary

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; IOHEXOL; IOMEPROL;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MALE; NECK CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION; WHOLE BODY IMAGING;

AGED; BIOPSY; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79960035419     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0918     Document Type: Article

References (31)

1. Schapira DV, Jarrett AR. The need to consider survival, outcome and expense when evaluating and treating patients with unknown primary carcinoma. Arch Intern Med 1995;155:2050.
2. Raber MN, Faintuch J, Abbruzzese JL, et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. Ann Oncol 1991;2:519.
3. Engzell U, Jacobsson PA, Sigurdson A, et al. Aspiration biopsy of metastatic carcinoma in lymph nodes of the neck. Acta Otolaryngol 1971;72:138.
4. Nordstrom DG, Tewfik HH, Latourette HB. Cervical lymph node metastases from an unknown primary. Int J Radiat Oncol Biol Phys 1979;5:73.
5. Leipzig B, Winter ML, Hokanson JA. Cervical node metastases of unknown origin. Laryngoscope 1981;91:593.
6. Regelink G, Brouwer J, de Bree R, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: Value of FDG-PET versus conventional modalities. Eur J Nucl Med 2002;29:1024.
7. Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003;260:436.
8. Muir C. Cancer of unknown primary site. Cancer 1995;75 (Suppl):353.
9. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 1994;6:1272.
10. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncologica 2007;46:592.
11. Million RR, Cassisi NJ, Mancuso AA. The unknown primary. In: Million RR, Cassisi NJ (eds.), Management of Head and Neck Cancer: A Multidisciplinary Approach, 2nd edition. Philadelphia: Lippincott, 1994;311.
12. Grau C, Johansen LV, Jacobsen J, et al. Cervical lymph node metastases from unknown primary tumours: Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000;55:121.
13. Johansen J, Eigtved A, Buchwald C, et al. Implication of 18Ffluoro- 2-deoxy-D-glucose positron emission tomography on themanagement of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 2002;112:1578.
14. Rades D, Kühnel G, Wildfang I, et al. Localised disease in cancer of unknown primary (CUP): The value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605.
15. Jungehülsing M, Scheidhauer K, Damm M, et al. 2(18F)- fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 2000;123:294.
16. Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumours. J Nucl Med 2000; 41:816.
17. Miller FR, Hussey D, Beeram M, et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 2005;131:626.
18. Greven KM, Keyes JW, Williams DW, et al. Occult primary tumours of the head and neck: Lack of benefit from positron emission tomography imaging with 2-(F-18)fluoro-2-deoxy- D-glucose. Cancer 1999;86:114.
19. Nieder C, Gregoire V, Ang K. Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001;50:727.
20. Stöckli SJ, Mosna-Firlejczyk K, Goerres GW. Lymph node metastasis of squamous cell carcinoma from an unknown primary: Impact of positron emission tomography. Eur J Nucl Med Mol Imaging 2003;30:411.
21. Kwee TC, Basu S, Cheng G, et al. FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2010; 37:635.
22. Mawlawi O, Townsend DW. Multimodality imaging: An update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009;36 (Suppl.1):S15.
23. Surti S, Kuhn A, Werner ME, et al. Performance of Philips Gemini TF PET/CT scanner with special considerations for its time-of-flight imaging capabilities. J Nucl Med 2007; 48:471.
24. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site- a hypothesis. Med Hypotheses 2002;59:357.
25. Naresh KN, Nerurkar AY, Borges AM. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 2001;38:466.
26. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumours: Systematic review and meta-analysis. Eur Radiol 2009;19:731.
27. Fakhry N, Barberet M, Lussato D, et al. Role of [18F]-FDG PET-CT in the management of the head and neck cancers. Bull Cancer 2006;93:1017.
28. Bruna C, Journo A, Netter F, et al. On the interest of PET with 18F-FDG in the management of cancer of unknown primary (CUP). Med Nucl 2007;31:242.
29. Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumor presenting with cervical metastases: Performance of hybrid FDG-PET-CT. Nucl Med Commun 2007;28:365.
30. Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography computed/computed tomography scan with 18F- fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging 2006;50:15.
31. Fencl P, Belohlavek O, Skopalova M, et al. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging 2007;34:1783.